Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P950021/S030

ADVIA Centaur PSA Immunoassay; Atellica IM Prostate-Specific Antigen (PSA)

Siemens Healthcare Diagnostics · Decision date Jul 16, 2025

FDA DECISIONP950021/S030

What did the FDA decide?

FDA records P950021/S030 as a supplement to PMA P950021, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 16, 2025.

FDA approval order statement

Approval for the implementation of a particle size analyzer utilized for the in-process testing of paramagnetic particles.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
Jul 16, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P950021/S030
Regulatory pathway
PMA supplement
Product code
MTG
Decision code
OK30
Decision date
Jul 16, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.

Product code
MTG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P950021/S030 received

    Application receipt date recorded by FDA.

  2. P950021/S030 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P950021. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MTG

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Medical Solutions Diagnostics LimitedPMA supplementSep 22, 2026FDA
Siemens Medical Solutions Diagnostics LimitedPMA supplementAug 20, 2026FDA
Siemens Medical Solutions Diagnostics LimitedPMA supplementJul 27, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA approvalMay 11, 2026FDA
Siemens Medical Solutions Diagnostics LimitedPMA supplementApr 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics

Headquarters
Not reported
FDA applicant address
333 Coney St., East Walpole, MA, 02032

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records